Cassava Sciences Inc. traded at $28.91 this Friday January 27th, increasing $1.00 or 3.58 percent since the previous trading session. Looking back, over the last four weeks, Cassava Sciences Inc. gained 3.92 percent. Over the last 12 months, its price fell by 27.27 percent. Looking ahead, we forecast Cassava Sciences Inc. to be priced at 33.69 by the end of this quarter and at 30.46 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
28.91
Daily Change
3.58%
Yearly
-27.27%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 8,149.00 -132.00 -1.59% 40.45%
Abbott 109.94 -1.12 -1.01% -12.29%
AcelRx Pharmaceuticals 1.99 0 0% 362.79%
Acura Pharmaceuticals 0.05 0 0% -89.36%
Amgen 253.65 -1.23 -0.48% 10.70%
Biogen 290.08 -1.84 -0.63% 28.80%
Cara Therapeutics 12.00 -0.27 -2.20% 8.79%
Geron 3.34 -0.03 -0.89% 212.15%
J&J 168.23 -0.66 -0.39% -2.07%
Eli Lilly 342.09 -5.91 -1.70% 39.57%
Merck & Co 105.38 -1.49 -1.39% 30.26%
Novartis 82.58 -0.10 -0.12% 4.04%
Novavax 11.29 0.31 2.82% -86.38%
Pfizer 43.79 -0.46 -1.04% -19.40%
Cassava Sciences Inc. 28.91 1.00 3.58% -27.27%
Roche Holding 289.35 0.35 0.12% -18.60%

Indexes Price Day Year
USND 11622 109.30 0.95% -15.60%
US2000 1911 8.39 0.44% -2.90%

Cassava Sciences Inc.
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimers disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimers brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimers disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimers disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.